{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-17T04:57:54.399077+00:00","published_at":"2026-10-17T04:46:39.768585+00:00","section":"events","data":{"state":"PUBLISHED","derivation_version":"alpha-governance-event-derivation-v2","events":[{"event_id":"alpha:event:transition:16g2xhi1r6dzoe","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-24","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:david-shook-m-d","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:13"],"evidence_ids":["alpha:projection-evidence:document:e4e1778b345e62bde7de98a4a5a81ef85040055ae32e0f8a8962d919b8db6bae"],"summary":"David Shook, M.D. executive of Lyell Immunopharma, Inc., effective 2026-04-24.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:11nt6ty46p5p","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-24","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:gary-lee-ph-d","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:14"],"evidence_ids":["alpha:projection-evidence:document:38d8832995f4cc3f87148dcbc7a1cdeec1e8280e4936cd4a2260980915404f64"],"summary":"Gary Lee, Ph.D. executive of Lyell Immunopharma, Inc., effective 2026-04-24.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1tnbau01qhwilo","event_type":"CEO_CHANGED","effective_at":"2026-04-24","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:lynn-seely-m-d","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:15"],"evidence_ids":["alpha:projection-evidence:document:a8feb7f4a9483c84c5f543aa45dcb5607d017ed17bd5def0c5925e2c84251646"],"summary":"Lynn Seely, M.D. executive of Lyell Immunopharma, Inc., effective 2026-04-24.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1mxdlrc1b283ig","event_type":"GC_CHANGED","effective_at":"2026-04-24","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:mark-meltz","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:16"],"evidence_ids":["alpha:projection-evidence:document:9def3689e80e3c3526608efc7c40f31eadbf1dc0d21c3d7ee72fbd9074cc775e"],"summary":"Mark Meltz executive of Lyell Immunopharma, Inc., effective 2026-04-24.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:urobrt8az3d7","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-24","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:smital-shah","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:17"],"evidence_ids":["alpha:projection-evidence:document:3f372c75ae285ef6bb9b63df09092aa44753680a9d1dbfc41e3cfc53e87b372c"],"summary":"Smital Shah executive of Lyell Immunopharma, Inc., effective 2026-04-24.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1oyeyyk1rdlrma","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-04-24","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:stephen-hill","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:18"],"evidence_ids":["alpha:projection-evidence:document:ed0feab478b28957f8d0a675bce18b4f21b00bcd083493cf90e96b8463d9cc4e"],"summary":"Stephen Hill executive of Lyell Immunopharma, Inc., effective 2026-04-24.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1lmln1pcl7kcp","event_type":"DIRECTOR_APPOINTED","effective_at":"2025-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:mark-j-bachleda-pharm-d-m-b-a","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Martine Rothblatt, Ph.D., J.D., M.B.A. seat on Lyell Immunopharma, Inc., effective 2025-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1qbnu6gyxi5k8","event_type":"DIRECTOR_APPOINTED","effective_at":"2024-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:sumant-ramachandra-m-d-ph-d","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Sumant Ramachandra, M.D., Ph.D. seat on Lyell Immunopharma, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1dpw14dqss3g7","event_type":"DIRECTOR_APPOINTED","effective_at":"2021-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:elizabeth-nabel","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Elizabeth Nabel seat on Lyell Immunopharma, Inc., effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1pp7242vp9gbu","event_type":"DIRECTOR_APPOINTED","effective_at":"2021-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:lynn-seely-m-d","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Lynn Seely, M.D. seat on Lyell Immunopharma, Inc., effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1iwagy417ryigc","event_type":"DIRECTOR_APPOINTED","effective_at":"2021-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:otis-brawley-m-d","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Otis Brawley, M.D. seat on Lyell Immunopharma, Inc., effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:11lac2bgapn7f","event_type":"COMMITTEE_CREATED","effective_at":"2021-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:committee:lyell-immunopharma-inc:audit-nominating-and-governance","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Audit; Nominating and Governance committee of Lyell Immunopharma, Inc., effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1nqvtlqonnc34","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2021-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:elizabeth-nabel","alpha:committee:lyell-immunopharma-inc:audit-nominating-and-governance"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Elizabeth Nabel member of Audit; Nominating and Governance, effective 2021-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:knovank0jbsf","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:william-rieflin","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"William Rieflin seat on Lyell Immunopharma, Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:5j2tj1ffdla7","event_type":"COMMITTEE_CREATED","effective_at":"2020-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:committee:lyell-immunopharma-inc:audit-chair-compensation","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Audit · Chair; Compensation committee of Lyell Immunopharma, Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:109pujn9s9omz","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2020-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:william-rieflin","alpha:committee:lyell-immunopharma-inc:audit-chair-compensation"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"William Rieflin member of Audit · Chair; Compensation, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1ora43oxx0oq6","event_type":"DIRECTOR_APPOINTED","effective_at":"2018-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:catherine-friedman","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Clifford J. Friedman seat on Lyell Immunopharma, Inc., effective 2018-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1efdc2mgyd9xi","event_type":"DIRECTOR_APPOINTED","effective_at":"2018-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:richard-klausner-m-d","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:10"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Richard Klausner, M.D. seat on Lyell Immunopharma, Inc., effective 2018-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1cmkcb6hgpmky","event_type":"COMMITTEE_CREATED","effective_at":"2018-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:committee:lyell-immunopharma-inc:audit-compensation-chair","alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Audit; Compensation · Chair committee of Lyell Immunopharma, Inc., effective 2018-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1tfne0q16gp3ry","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2018-01-01","detected_at":"2026-10-17T04:46:39.768585+00:00","subject_ids":["alpha:person:catherine-friedman","alpha:committee:lyell-immunopharma-inc:audit-compensation-chair"],"caused_claim_ids":["alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7"],"summary":"Clifford J. Friedman member of Audit; Compensation · Chair, effective 2018-01-01.","derivation":"temporal_relationship_change"}]},"claims":[{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:5","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:catherine-friedman","object_label":"Clifford J. Friedman","object_source_name_forms":[],"value":"Clifford J. Friedman: Director, Audit; Compensation · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:catherine-friedman","name":"Clifford J. Friedman"},"title":"Director","role_category":"director","committee":"Audit; Compensation · Chair","is_board_chair":false,"is_independent":true,"start_date":"2018-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2018-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24","effective_from":"2018-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:6","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:elizabeth-nabel","object_label":"Elizabeth Nabel","object_source_name_forms":[],"value":"Elizabeth Nabel: Director, Audit; Nominating and Governance","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:elizabeth-nabel","name":"Elizabeth Nabel"},"title":"Director","role_category":"director","committee":"Audit; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:7","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:lynn-seely-m-d","object_label":"Lynn Seely, M.D.","object_source_name_forms":[],"value":"Lynn Seely, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:lynn-seely-m-d","name":"Lynn Seely, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:8","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:mark-j-bachleda-pharm-d-m-b-a","object_label":"Martine Rothblatt, Ph.D., J.D., M.B.A.","object_source_name_forms":[],"value":"Martine Rothblatt, Ph.D., J.D., M.B.A.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:mark-j-bachleda-pharm-d-m-b-a","name":"Martine Rothblatt, Ph.D., J.D., M.B.A."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2025-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2025-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24","effective_from":"2025-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:9","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:otis-brawley-m-d","object_label":"Otis Brawley, M.D.","object_source_name_forms":[],"value":"Otis Brawley, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:otis-brawley-m-d","name":"Otis Brawley, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:10","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:richard-klausner-m-d","object_label":"Richard Klausner, M.D.","object_source_name_forms":[],"value":"Richard Klausner, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:richard-klausner-m-d","name":"Richard Klausner, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2018-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2018-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24","effective_from":"2018-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:11","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:sumant-ramachandra-m-d-ph-d","object_label":"Sumant Ramachandra, M.D., Ph.D.","object_source_name_forms":[],"value":"Sumant Ramachandra, M.D., Ph.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:sumant-ramachandra-m-d-ph-d","name":"Sumant Ramachandra, M.D., Ph.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2024-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24","effective_from":"2024-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:12","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:william-rieflin","object_label":"William Rieflin","object_source_name_forms":[],"value":"William Rieflin: Director, Audit · Chair; Compensation","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:william-rieflin","name":"William Rieflin"},"title":"Director","role_category":"director","committee":"Audit · Chair; Compensation","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:13","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:david-shook-m-d","object_label":"David Shook, M.D.","object_source_name_forms":[],"value":"David Shook, M.D.: Chief Medical Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:david-shook-m-d","name":"David Shook, M.D."},"title":"Chief Medical Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-24","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-24","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:e4e1778b345e62bde7de98a4a5a81ef85040055ae32e0f8a8962d919b8db6bae","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:12.496119+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24T00:00:00+00:00","effective_from":"2026-04-24","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:14","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:gary-lee-ph-d","object_label":"Gary Lee, Ph.D.","object_source_name_forms":[],"value":"Gary Lee, Ph.D.: Chief Scientific Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:gary-lee-ph-d","name":"Gary Lee, Ph.D."},"title":"Chief Scientific Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-24","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-24","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:38d8832995f4cc3f87148dcbc7a1cdeec1e8280e4936cd4a2260980915404f64","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:11.068772+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24T00:00:00+00:00","effective_from":"2026-04-24","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:15","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:lynn-seely-m-d","object_label":"Lynn Seely, M.D.","object_source_name_forms":[],"value":"Lynn Seely, M.D.: President, Chief Executive Officer and Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:lynn-seely-m-d","name":"Lynn Seely, M.D."},"title":"President, Chief Executive Officer and Director","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-24","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-24","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:a8feb7f4a9483c84c5f543aa45dcb5607d017ed17bd5def0c5925e2c84251646","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:10.113662+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24T00:00:00+00:00","effective_from":"2026-04-24","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:16","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:mark-meltz","object_label":"Mark Meltz","object_source_name_forms":[],"value":"Mark Meltz: General Counsel and Corporate Secretary","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:mark-meltz","name":"Mark Meltz"},"title":"General Counsel and Corporate Secretary","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-24","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-24","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:9def3689e80e3c3526608efc7c40f31eadbf1dc0d21c3d7ee72fbd9074cc775e","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:11.559133+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24T00:00:00+00:00","effective_from":"2026-04-24","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:17","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:smital-shah","object_label":"Smital Shah","object_source_name_forms":[],"value":"Smital Shah: Chief Financial and Business Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:smital-shah","name":"Smital Shah"},"title":"Chief Financial and Business Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-24","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-24","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:3f372c75ae285ef6bb9b63df09092aa44753680a9d1dbfc41e3cfc53e87b372c","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:12.00704+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24T00:00:00+00:00","effective_from":"2026-04-24","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:18","subject_id":"alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:stephen-hill","object_label":"Stephen Hill","object_source_name_forms":[],"value":"Stephen Hill: Chief Operating Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:stephen-hill","name":"Stephen Hill"},"title":"Chief Operating Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-04-24","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-04-24","valid_to":null,"recorded_at":"2026-10-17T04:46:39.768585+00:00","sources":[{"id":"alpha:projection-evidence:document:ed0feab478b28957f8d0a675bce18b4f21b00bcd083493cf90e96b8463d9cc4e","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:10.580223+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-24T00:00:00+00:00","effective_from":"2026-04-24","effective_until":null,"observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Lyell Immunopharma, Inc. DEF 14A 2026-04-24","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24","retrieved_at":"2026-04-24T23:31:00.497+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:e4e1778b345e62bde7de98a4a5a81ef85040055ae32e0f8a8962d919b8db6bae","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:12.496119+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:38d8832995f4cc3f87148dcbc7a1cdeec1e8280e4936cd4a2260980915404f64","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:11.068772+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:a8feb7f4a9483c84c5f543aa45dcb5607d017ed17bd5def0c5925e2c84251646","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:10.113662+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:9def3689e80e3c3526608efc7c40f31eadbf1dc0d21c3d7ee72fbd9074cc775e","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:11.559133+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:3f372c75ae285ef6bb9b63df09092aa44753680a9d1dbfc41e3cfc53e87b372c","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:12.00704+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:ed0feab478b28957f8d0a675bce18b4f21b00bcd083493cf90e96b8463d9cc4e","identity_scope":"source_document_reference","source_type":"sec_filing","title":"LYEL DEF 14A executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm","source_date":"2026-04-24T00:00:00+00:00","retrieved_at":"2026-05-16T05:07:10.580223+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.846,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.904,"cross_source_agreement":0.75,"temporal_completeness":0.7},"diagnostics":{"published_claims":27,"factual_claims":27,"claims_with_linked_evidence":27,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":20,"temporal_claims_with_valid_from":14,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-17T04:46:39.768585+00:00","observed_at":"2026-10-17T04:46:39.768585+00:00","reviewed_at":"2026-10-17T04:46:39.768585+00:00","verified_at":"2026-10-17T04:46:39.768585+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":27,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/lyell-immunopharma-inc/events","section":"events","href":"https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record&section=events","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}